Table 3

Univariate analysis of immunohistochemical findings and their association with axillary lymph node metastasis

Factor

Unadjusted odd ratio and

95% confidence interval

ALNM negative

(n = 94)

ALNM positive

(n = 116)

P value

ER

1.14 (0.62-2.07)

63/92 (68.5%)

79/111 (71.2%)

0.677

PR

1.13 (0.62-2.07)

64/92 (69.6%)

80/111 (72.1%)

0.695

HER2

1.28 (0.64-2.56)

17/92 (18.5%)

25/111 (22.5%)

0.479

CK5

0.25 (0.10-0.61)

21/86 (24.4%)

7/95 (7.4%)

0.002

CK14

0.28 (0.09-0.91)

12/73 (16.4%)

4/77 (5.2%)

0.034

CK17

0.38 (0.09-1.52)

7/72 (9.7%)

3/77 (3.9%)

0.198

P53

0.95 (0.48-1.88)

23/71 (32.4%)

25/80 (31.3%)

0.880

Ki67

1.51 (0.80-2.82)

33/78 (42.3)

42/80 (52.5%)

0.200

EGFR

0.35 (0.15-0.82)

20/61 (32.8%)

10/69 (14.5%)

0.013

ER/PR/HER2 profile

ER/PR+, HER2-

Reference

59/92 (64.1%)

71/111 (64.0%)

ER/PR+, HER2+

1.50 (0.48-4.70)

5/92 (5.4%)

9/111 (8.1%)

0.488

ER/PR-, HER2+

1.11 (0.49-2.53)

12/92 (13.0%)

16/111 (14.4%)

0.806

ER/PR-, HER2-

0.78 (0.36-1.71)

16/92 (17.4%)

15/111 (13.5%)

0.532

Triple-negative tumor

0.74 (0.35-1.60)

16/92 (17.4%)

15/111 (13.5%)

0.445

Basal-like tumor

0.25 (0.08-0.80)

12/92 (13.0%)

4/111 (3.6%)

0.017

Unless otherwise stated, data are expressed as n (%).ALNM, axillary lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; CK, cytokeratin

Yenidunya et al. Diagnostic Pathology 2011 6:18   doi:10.1186/1746-1596-6-18